Clinical Trial Update: EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19 [Phase 2, Phase 3]

View source ↗

Summary

An update on effectiveness, safety, and immunogenicity of a half-dose ChadOx1 nCoV-19 (AZD1222) COVID-19 vaccine regimen evaluated in Phase 2/Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars-cov-2

Drugs mentioned

• ChAdOx1 nCoV-19

Snippet

Sponsor: Federal University of Espirito Santo | Conditions: SARS-CoV-2 | Phase 2, Phase 3 | Status: UNKNOWN